AstraZeneca PLC (LON:AZN)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 175.47B |
| Revenue (ttm) | 43.19B |
| Net Income (ttm) | 5.62B |
| Shares Out | 1.55B |
| EPS (ttm) | 3.59 |
| PE Ratio | 31.48 |
| Forward PE | 16.51 |
| Dividend | 2.46 (2.14%) |
| Ex-Dividend Date | Feb 20, 2025 |
| Volume | 2,306,821 |
| Average Volume | 2,775,579 |
| Open | 11,452 |
| Previous Close | 11,452 |
| Day's Range | 11,316 - 11,576 |
| 52-Week Range | 9,670 - 13,388 |
| Beta | 0.16 |
| RSI | 38.19 |
| Earnings Date | Apr 29, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
After China probe, is AstraZeneca’s new US$2.5 billion plan a blueprint for foreign firms?
British-Swedish drug maker has gone from Beijing’s scrutiny to its praise, hailed as a sign of doing business in China.
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
The Association of the British Pharmaceutical Industry (ABPI) is urging ministers to address excessive levies on manufacturers to ensure the sector remains competitive globally. The life sciences indu...
AstraZeneca CEO on its $2.5 billion investment in Beijing hub
British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in the Chinese capital.
AstraZeneca to invest $2.5bn in drugs research and manfacturing in Beijing
Pharmaceutical company will invest money over five years in ‘strategic partnership’ with the city’s authorities Business live – latest updates AstraZeneca will invest $2.5bn in research and manufactur...
AstraZeneca to Invest $2.5 Billion in China Amid Probes
The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies, at a time when Chinese authorities are probing it.
Watch CNBC's full interview with AstraZeneca CEO Pascal Soriot
Pascal Soriot, CEO of British pharmaceutical giant AstraZeneca, discusses the company's $2.5 billion investment in a new China research and development center.
Watch CNBC's full interview with Pascal Soriot, AstraZeneca CEO
Pascal Soriot, CEO, AstraZeneca discusses the company's $2.5 billion investment in its new China research and development centre.
Watch CNBC's full interview with AstraZeneca CEO Pascal Soriot on its $2.5 billion China investment
Pascal Soriot, CEO of British pharmaceutical giant AstraZeneca, discusses the company's $2.5 billion investment in a new China research and development center.
AstraZeneca expands in China with a $2.5B investment in Beijing
AstraZeneca to invest $2.5bn in China after scandal
London-listed drugmaker will establish research centre in Beijing
Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies
SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands , March 21, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and comm...
British pharma giant AstraZeneca to invest $2.5 billion in new China hub
British pharmaceutical giantAstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing, China.
AstraZeneca investing $2.5 bln in China as drugmaker seeks to recover from scandals
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including ...
Stock Market Today: Welspun Corp, Nuvama, AstraZeneca, Bharti Airtel, Aavas Financiers hit 52-week highs on March 20, 2025
The stock market witnessed a strong rally in several stocks on March 20, 2025, with Welspun Corp, Nuvama, AstraZeneca, Bharti Airtel, and Aavas Financiers touching their 52-week highs. These stocks sa...
Mindpeak to deploy and evaluate AI-Powered Digital Pathology Risk Assessment Tools for Breast Cancer in collaboration with AstraZeneca
HAMBURG, Germany--(BUSINESS WIRE)--The collaboration aims to assess the transformative potential of AI in digital pathology, with a specific focus on accelerating primary breast cancer diagnosis. Brea...
IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals
CAMBRIDGE, United Kingdom , March 17, 2025 /PRNewswire/ -- IgniteData has announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) and Cambridge University Hospitals NHS Foundation Trust (CUH)...
AstraZeneca to buy cell therapy biotech for up to $1 billion
AstraZeneca will pay $425 million upfront for EsoBiotec and may spend up to $575 million more in development and regulatory milestones, the companies said.
AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details
EsoBiotec SA , a biotechnology company specializing in in vivo cell therapies, has announced a definitive agreement to be acquired by AstraZeneca PLC (NYSE: AZN). The agreement represents a major ste...
AstraZeneca pays up to $1bn for biotech firm ‘that could transform cell therapy’
UK pharma group acquires Belgium’s EsoBiotec as it announces EU has approved Imfinzi lung cancer drug Business live – latest updates AstraZeneca has struck a $1bn (£773m) deal to buy a Belgian biotech...
AstraZeneca buys cell therapy biotech in up to $1bn deal
London-listed pharmaceuticals group expands investments in cancer cell therapies with EsoBiotec acquisition
AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio
AstraZeneca to buy EsoBiotec to advance cell therapy ambition
AstraZeneca to buy EsoBiotec in $1 billion deal to advance cell therapy ambition
AstraZeneca to buy Esobiotec for upto $1 billion
Drugmaker AstraZeneca on Monday said it will buy biotechnology firm Esobiotec for upto $1 billion.
EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition
Acquisition includes EsoBiotec's world-leading in vivo delivery platform with potential to transform cell therapy Acquisition includes EsoBiotec's world-leading in vivo delivery platform with potentia...